Poultsides George A, Servais Elliot L, Saltz Leonard B, Patil Sujata, Kemeny Nancy E, Guillem Jose G, Weiser Martin, Temple Larissa K F, Wong W Douglas, Paty Phillip B
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
J Clin Oncol. 2009 Jul 10;27(20):3379-84. doi: 10.1200/JCO.2008.20.9817. Epub 2009 Jun 1.
The purpose of this study was to describe the frequency of interventions necessary to palliate the intact primary tumor in patients who present with synchronous, stage IV colorectal cancer (CRC) and who receive up-front modern combination chemotherapy without prophylactic surgery.
By using a prospective institutional database, we identified 233 consecutive patients from 2000 through 2006 with synchronous metastatic CRC and an unresected primary tumor who received oxaliplatin- or irinotecan-based, triple-drug chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin; bolus fluorouracil, leucovorin, and irinotecan; or fluorouracil, leucovorin, and irinotecan) with or without bevacizumab as their initial treatment. The incidence of subsequent use of surgery, radiotherapy, and/or endoluminal stenting to manage primary tumor complications was recorded.
Of 233 patients, 217 (93%) never required surgical palliation of their primary tumor. Sixteen patients (7%) required emergent surgery for primary tumor obstruction or perforation, 10 patients (4%) required nonoperative intervention (ie, stent or radiotherapy), and 213 (89%) never required any direct symptomatic management for their intact primary tumor. Of those 213 patients, 47 patients (20%) ultimately underwent elective colon resection at the time of metastasectomy, and eight patients (3%) underwent this resection during laparotomy for hepatic artery infusion pump placement. Use of bevacizumab, location of the primary tumor in the rectum, and metastatic disease burden were not associated with increased intervention rate.
Most patients with synchronous, stage IV CRC who receive up-front modern combination chemotherapy never require palliative surgery for their intact primary tumor. These data support the use of chemotherapy, without routine prophylactic resection, as the appropriate standard practice for patients with neither obstructed nor hemorrhaging primary colorectal tumors in the setting of metastatic disease.
本研究旨在描述对于同时性IV期结直肠癌(CRC)患者,在未进行预防性手术的情况下接受一线现代联合化疗时,缓解完整原发肿瘤所需干预措施的频率。
通过前瞻性机构数据库,我们确定了2000年至2006年期间连续的233例同时性转移性CRC且原发肿瘤未切除的患者,这些患者接受了以奥沙利铂或伊立替康为基础的三联化疗(持续输注氟尿嘧啶、亚叶酸钙和奥沙利铂;推注氟尿嘧啶、亚叶酸钙和伊立替康;或氟尿嘧啶、亚叶酸钙和伊立替康),初始治疗时使用或未使用贝伐单抗。记录后续使用手术、放疗和/或腔内支架置入术处理原发肿瘤并发症的发生率。
233例患者中,217例(93%)从未需要对其原发肿瘤进行手术姑息治疗。16例患者(7%)因原发肿瘤梗阻或穿孔需要急诊手术,10例患者(4%)需要非手术干预(即支架或放疗),213例(89%)从未需要对其完整原发肿瘤进行任何直接的对症处理。在这213例患者中,47例患者(20%)最终在转移灶切除时接受了择期结肠切除术,8例患者(3%)在剖腹术放置肝动脉灌注泵时进行了该切除术。贝伐单抗的使用、原发肿瘤位于直肠的位置以及转移疾病负担与干预率增加无关。
大多数接受一线现代联合化疗的同时性IV期CRC患者,其完整原发肿瘤从未需要姑息性手术。这些数据支持在转移性疾病背景下,对于既无梗阻也无出血的原发性结直肠肿瘤患者,使用化疗而非常规预防性切除作为合适的标准治疗方法。